|
Dr. Janes is the Senior Vice President, Intellectual Property and Technology Development, and Chief Patent Officer of QLT (since November 2015). She joined QLT in August 2005 and has held positions of increasing responsibility in intellectual property and, since 2007, has overseen all aspects of global intellectual property matters for QLT. In January 2010, Dr. Janes was appointed Vice President, Intellectual Property and Chief Patent Officer. In March 2015, Dr. Janes assumed additional responsibilities in QLT’s research & development functions and, as of September 2015, assumed responsibility for the oversight and management of all research and development related activities for QLT’s synthetic retinoid program. Dr. Janes brings over 20 years of intellectual property and pharmaceutical development experience to her roles at QLT.
Prior to joining QLT, Dr. Janes worked for several years as a registered patent agent in the Toronto offices of Blake, Cassels & Graydon LLP, and Ogilvy Renault LLP (now Norton Rose Fulbright), and has also served as an in-house patent agent at F. Hoffmann-La Roche in Basel, Switzerland, where her practice focused on the strategic development and protection of IP portfolios in the fields of pharmaceutical and biological products.
Dr. Janes received her AB in Chemistry from Harvard University and her Ph.D. in organic chemistry from McGill University, where she also conducted post-Doctoral work in the field of biological organic chemistry. Dr. Janes is also a registered patent agent in both Canada and the United States. She is an author of numerous scientific publications in the field of organic and medical chemistry and worked for several years as a synthetic organic chemist in the chemical and food industries. Dr. Janes currently serves on the Board of Phoenix Molecular Designs, a privately held pharmaceutical company located in Vancouver, Canada.
|
